| Patient | Muhammad Ali |
|---|---|
| Date of birth | 1942-01-17 |
| Identifiers | MRN HR-BX001-SYN-TD; SSN (made up) 000-01-7724 |
| Document date | 1996-06-09 |
| Author | Celeste Moreau, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Three-month Parkinson's disease review after the levodopa increase and speech therapy. [S]
Mr. Ali returns three months after his first visit. Since carbidopa-levodopa was increased to one and a half tablets three times a day, taken 30 minutes before meals, he is quicker with buttons and getting out of chairs, and the late-morning slowness has eased. He has had no involuntary movements, no wearing-off before doses, and no lightheadedness on standing, nausea, or sleepiness. He finished the four-week LSVT LOUD speech therapy course two months ago and practices his voice exercises each day; people hear him more easily. He has had six physical therapy sessions and now walks, rides a stationary bicycle, and does balance exercises about 150 minutes a week. He has had no falls. He has had no hallucinations. [S]
| Element | Detail |
|---|---|
| Medicine change | Levodopa 150 mg three times daily before meals for twelve weeks; slowness better |
| Motor complications | No dyskinesia or wearing-off |
| Rehabilitation | LSVT LOUD course completed; six physical therapy sessions; home program about 150 minutes a week |
| Falls | None |
| System | Result | Finding |
|---|---|---|
| Cardiovascular | Negative | No lightheadedness on standing or fainting |
| Gastrointestinal | Negative | No nausea or constipation |
| Neurological | Positive | Slowness improved; mild right-hand tremor; no involuntary movements or freezing |
| Psychiatric | Negative | Mood good; no hallucinations |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Carbidopa-levodopa 25/100 mg oral tablet, one tablet by mouth three times daily | One tablet by mouth three times daily, at about 7 a.m., noon, and 5 p.m. | Oral route | 1984-10-01 to 1996-03-10 | completed | S |
| Carbidopa-levodopa 25/100 mg oral tablet, one and a half tablets by mouth three times daily, 30 minutes before meals | One and a half tablets (levodopa 150 mg) by mouth three times daily, 30 minutes before meals | Oral route | 1996-03-10 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1996-06-09 | Body height | 191 | cm | S |
| 1996-06-09 | Body weight | 101.5 | kg | S |
| 1996-06-09 | Body mass index (BMI) [Ratio] | 27.8 | kg/m2 | S |
| 1996-06-09 | Systolic blood pressure | 124 | mm[Hg] | S |
| 1996-06-09 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 1996-06-09 | Heart rate | 72 | /min | S |
| 1996-06-09 | Respiratory rate | 14 | /min | S |
| 1996-06-09 | Body temperature | 36.7 | Cel | S |
| 1996-06-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
Vital signs recorded on 1996-06-09; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Alert and engaged; voice noticeably louder in conversation |
| Cardiovascular | Regular rhythm at 72 per minute. Blood pressure 126/78 mmHg supine and 116/76 mmHg after 3 minutes standing, a 10 mmHg fall in systolic pressure, without symptoms; no orthostatic hypotension |
| Neurological | On state: MDS-UPDRS Part III 24, down from 30; Hoehn and Yahr stage 2.5; milder bradykinesia and rigidity; mild right-hand rest tremor; no dyskinesia |
| Gait | Longer steps and better arm swing; recovers after two steps on the pull test; Timed Up and Go 11 seconds |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Parkinson's disease, young onset (diagnosed at 42), Hoehn and Yahr stage 2.5, without dyskinesia or motor fluctuations | active | confirmed | G20.A1 | S — Synthetic modern coding of the publicly disclosed diagnosis; the stage and the absence of motor complications are synthetic. |
| Hypokinetic dysarthria with soft speech due to Parkinson's disease | active | confirmed | R47.1 | S — Synthetic modern coding of the publicly reported speech difficulty; the severity is synthetic. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | MDS-UPDRS Parts III and IV and Hoehn and Yahr stage | Every visit | Completed today | Part III 24, down from 30; Hoehn and Yahr 2.5; Part IV: no dyskinesia, wearing-off, or on-off |
| Examination | Orthostatic blood pressure, supine and after 3 minutes standing | Every visit while on dopaminergic treatment | Completed today | 126/78 mmHg supine and 116/76 mmHg at 3 minutes standing after the dose increase; no orthostatic hypotension |
| Medication safety | Dopaminergic regimen review for wearing-off, dyskinesia, and on-off | Every visit | Completed today | Good response to levodopa 150 mg three times daily with no motor complications; no change |
| Medication safety | Avoidance of dopamine-blocking drugs | Every visit | Completed today | No dopamine-blocking drugs |
| Medication safety | Medication side effects and adherence | Every visit | Completed today | No nausea, sleepiness, or missed doses; doses now taken before meals |
| Examination | Fall query and fall-risk assessment (Timed Up and Go, pull test) | Every visit | Completed today | No falls; Timed Up and Go 11 seconds, improved from 13; recovers after two steps on the pull test |
| Survey | Psychotic symptoms (hallucinations, delusions) | Every visit | Completed today | None |
| Survey | Impulse-control screen (QUIP-RS) | Every visit; mandatory on a dopamine agonist | Deferred | Not asked at this visit, a deviation from the every-visit item. He is not on a dopamine agonist, and the screen at the six-month review was negative, so no impulse-control problem was missed. Corrective action: the screen is added to the standing visit checklist |
| Self-management | Exercise counseling: aerobic, resistance, and balance, at least 150 minutes a week | Every visit | Completed today | About 150 minutes a week of walking, cycling, and balance exercises |
| Self-management | Advance care planning and goals of care | At diagnosis and at least yearly | Due | Planned for the preventive visit in the autumn |
| Examination | Diagnosis review against the MDS clinical diagnostic criteria | Yearly | Up to date | Confirmed by neurology three months ago |
| Survey | Cognitive screen (MoCA) | At least yearly | Up to date | MoCA 27 of 30 four months ago |
| Survey | Depression, anxiety, and apathy (PHQ-9) | At least yearly | Up to date | PHQ-9 3 four months ago; mood good today |
| Survey | Sleep: REM sleep behavior disorder questionnaire, Epworth Sleepiness Scale, insomnia, restless legs | At least yearly | Up to date | No dream enactment or daytime sleepiness |
| Survey | Autonomic symptoms: constipation, urinary, sexual, sweating, drooling | At least yearly | Up to date | No constipation or urinary symptoms |
| Survey | Swallowing screen (EAT-10) | At least yearly | Up to date | EAT-10 2 four months ago; no choking or coughing with meals since |
| Examination | Speech and voice loudness | Yearly; speech therapy for speech change | Completed today | LSVT LOUD course completed; louder speech today |
| Referral | Physical, occupational, and speech therapy | At diagnosis, then reassessed yearly | Completed today | Speech therapy completed; physical therapy in progress, moving to a home program |
| Laboratory | Genetic testing with counseling | Once, offered to every person with Parkinson's disease | Due | Offered three months ago; decision at the yearly neurology review |
| Examination | Dental and oral examination | Every 6 months | Due | Not yet arranged; due by six months |
| Examination | Driving safety | Yearly or with a motor or cognitive change | Up to date | Motor function better; review yearly |
| Self-management | Vaccination status (influenza, pneumococcal, zoster, COVID-19, Tdap) | Yearly, per the CDC schedule | Due | To be reviewed at the preventive visit in the autumn |
| Laboratory | Routine laboratory monitoring | Not required for Parkinson's disease surveillance | Not indicated | The CMID monograph calls for no routine laboratory tests; baseline blood count, chemistry, vitamin B12, and TSH were normal at the first visit |
| Imaging | Brain MRI | If atypical parkinsonism features appear | Not indicated | No atypical features; examination unchanged apart from the improvement |
| Imaging | Polysomnography for REM sleep behavior disorder | If REM sleep behavior disorder treatment is considered | Not indicated | No dream enactment |
| Medication safety | AGS Beers Criteria medication review | Yearly from age 65 | Not indicated | He is 54 |
| Examination | Deep brain stimulation programming review | Every 6 to 12 months after implantation | Not indicated | No deep brain stimulator |
Goal progress:
Guideline basis: Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee (2021); MDS clinical diagnostic criteria for Parkinson's disease (2015); The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension (2017); CMID: Clinical Monitoring Intelligence Database, Parkinson's disease monograph (2026)
Follow-up: Six-month Parkinson's disease review in three months. Next scheduled visit 1996-09-08: six-month Parkinson's disease review. [S]